# Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging

> **NCT01221272** · PHASE4 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 81 (actual)

## Conditions studied

- Myocardial Perfusion Imaging
- Myocardial Ischemia

## Interventions

- **DRUG:** Ranolazine
- **DRUG:** Placebo to match ranolazine
- **PROCEDURE:** SPECT MPI
- **BEHAVIORAL:** Exercise

## Key facts

- **NCT ID:** NCT01221272
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2014-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01221272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01221272, "Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01221272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*